Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Satraplatin is an orally available antineoplastic platinum(IV) complex.Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies.
Description | Satraplatin is an orally available antineoplastic platinum(IV) complex.Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies. |
In vitro | KB-R cells did not show cross-resistance to satraplatin. The expression status of almost all transporters was upregulated in the KB-R cells. There was no difference in the GSH levels between the KB and KB-R cells. Flow cytometric analysis indicated that with satraplatin the G2/M phase was arrested in the KB-R cells. KB-R cells contain enriched side population cells[1]. |
Cell Research | CDDP-resistant (KB-R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real-time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment[1]. |
Synonyms | BMS182751, 沙铂, JM216, 顺式-二氯-反式-二乙酸-氨-环己胺合铂, BMY45594 |
Molecular Weight | 498.26 |
Formula | C10H20Cl2N2O4Pt |
CAS No. | 129580-63-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 33 mg/mL (65.96 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Satraplatin 129580-63-8 DNA损伤和修复 DNA Alkylation DNA Alkylator/Crosslinker BMY 45594 JM216 BMS-182751 BMY-45594 BMS182751 JM 216 inhibit Inhibitor BMS 182751 BMY45594 JM-216 inhibitor